Preclinical News and Research

RSS

Pathophysiological abnormalities in preclinical phase of AD may be detected using CSF or neuroimaging biomarkers

Both A- and tau pathology appear to be associated with default mode network integrity before clinical onset of Alzheimer disease (AD), according to a study by Liang Wang, M.D., and colleagues at Washington University in St. Louis, Missouri.

20 Aug 2013

Tigercat and Velocity Pharmaceutical announce submission of IND application to FDA for VPD-737

Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") announced today the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for VPD-737 for the treatment of chronic pruritus.

19 Aug 2013

New type of cancer immunotherapy harnesses body's immune system to attack tumors

By carefully adjusting the function of crucial immune cells, scientists may have developed a completely new type of cancer immunotherapy—harnessing the body's immune system to attack tumors. To accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responses.

19 Aug 2013

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B.

17 Aug 2013

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.

17 Aug 2013

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2013

GHI research aims to target breast cancer stem-like cells using immunotherapy

New hope is on its way for the fight against breast cancer as Griffith Health Institute research aims to target the disease with immune-based therapies.

16 Aug 2013

Novel potential biomarker present in CSF reveals signs of dementia decade before

A study published today reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD). The results suggest that this novel potential biomarker is present in cerebral spinal fluid (CSF) at least a decade before signs of dementia manifest.

16 Aug 2013

Researchers identify key mechanism behind aggressive prostate cancer

A team of researchers from UC Davis, UC San Diego and other institutions has identified a key mechanism behind aggressive prostate cancer. Published on August 14 in Nature, the study shows that two long non-coding RNAs (PRNCR1 and PCGEM1) activate androgen receptors, circumventing androgen-deprivation therapy.

16 Aug 2013

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

Osteoarthritis is an extremely common condition affecting about 8 million people in the UK. The elderly are particularly susceptible, with up to 45% of people over 65 years, having the disease.

14 Aug 2013

New test hints 3 sodas daily hurt lifespan, reproduction in mice

When mice ate a diet of 25 percent extra sugar - the mouse equivalent of a healthy human diet plus three cans of soda daily - females died at twice the normal rate and males were a quarter less likely to hold territory and reproduce, according to a toxicity test developed at the University of Utah.

14 Aug 2013

Discovery Transformation Program funds four projects for diabetes research

The Minnesota Partnership for Biotechnology and Medical Genomics announced four research projects selected for funding from the 2013 Discovery Transformation Grant Program.

13 Aug 2013

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.

13 Aug 2013

New research opens door for development of treatments capable of stopping Alzheimer's disease

New research just out in the journal Science Translational Medicine opens the door for the development of treatments capable of stopping Alzheimer's disease (AD) before its first symptoms, that is to say before any crucial damage occurs. In fact, if AD is a devastating disorder it is also an extremely slow one; it takes more than 10 years for the first symptoms to appear making this preclinical period (pre-symptoms) the ideal time to intervene.

13 Aug 2013

Cedars-Sinai launches Phase I clinical trial to study tolerability of immunization to treat Alzheimer's disease

Cedars-Sinai Medical Center has launched a Phase I clinical trial to study the safety and tolerability of an experimental immunization to treat Alzheimer's disease. The treatment is based on Copaxone (glatiramer acetate), a drug often prescribed to reduce the frequency of multiple sclerosis relapses.

13 Aug 2013

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells to inhibit proliferation. According to BreastCancer.org 1 in 8 women in the U.S. will develop invasive breast cancer and more than 39,000 deaths occur annually.

12 Aug 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

AmpliPhi BioSciences Corp. (OTC: APHB) ("AmpliPhi"), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment of Pseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held in Olympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.

8 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

Preclinical News and Research

Pathophysiological abnormalities in preclinical phase of AD may be detected using CSF or neuroimaging biomarkers

Tigercat and Velocity Pharmaceutical announce submission of IND application to FDA for VPD-737

New type of cancer immunotherapy harnesses body's immune system to attack tumors

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

DLBCLs resistant to chemotherapy can be reprogrammed to respond using azacitidine

GHI research aims to target breast cancer stem-like cells using immunotherapy

Novel potential biomarker present in CSF reveals signs of dementia decade before

Researchers identify key mechanism behind aggressive prostate cancer

Osteoarthritis research: an interview with Dr Deborah Mason, Cardiff University

New test hints 3 sodas daily hurt lifespan, reproduction in mice

Discovery Transformation Program funds four projects for diabetes research

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

New research opens door for development of treatments capable of stopping Alzheimer's disease

Cedars-Sinai launches Phase I clinical trial to study tolerability of immunization to treat Alzheimer's disease

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Bayer Collaboration Could Net $540M+ For Compugen

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics